Aurobindo Pharma Limited has announced that a meeting of its Board of Directors is scheduled for May 21, 2026. The primary objective of the meeting is to review and approve the standalone and consolidated audited financial results for the fourth quarter and the financial year ended March 31, 2026.
Upcoming Financial Review
The Board of Directors of Aurobindo Pharma is set to convene on Thursday, May 21, 2026. During this session, the leadership team will evaluate the company’s financial performance for the final quarter (January to March) and the complete 2025-26 fiscal year.
Trading Window Update
In accordance with the company’s internal code of conduct, the trading window for securities of Aurobindo Pharma has been closed since April 1, 2026. This restriction will continue through May 23, 2026, to ensure compliance during the period surrounding the financial results announcement. The trading window is scheduled to officially reopen on May 24, 2026.
Source: BSE
